PATENT CLAIM ANALYSIS

Application Number: 16193762
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "183000"]

Abstract:
The subject invention relates to diffusion enhancing compounds and their use alone or with thrombolytic agents for the treatment of disorders resulting from the formation of a thrombus such as a myocardial infarction or stroke.

Claim (Index 17):
A method as in  claim 5  wherein the diffusion enhancing compound is administered within 4 hours of the onset of stroke symptoms and the thrombolytic agent is administered within 12 hours of the onset of stroke symptoms.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 98.0
- Lexical Diversity: 1.125
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12801726', '12081236', '13137322', '13067469', '13189413']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7463942742947495
- 35 USC 102 Novelty (BERT): 0.5781781736012525
- Combined Prediction Score: 0.7295726642253998
- Mean Citation Score: 310.9016620000001
- Max Citation Score: 500.5659
- Similarity Product: 362.2359051362336

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test